leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...203204205206207208209210211212213...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
    Trial primary completion date, Metastases:  Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Dec 6, 2015   
    P2,  N=43, Recruiting, 
    Trial primary completion date: Nov 2015 --> Jun 2016
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Trial primary completion date, Metastases:  Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) -  Dec 6, 2015   
    P1,  N=16, Active, not recruiting, 
    Trial primary completion date: Nov 2015 --> Jun 2016 Trial primary completion date: Feb 2016 --> Jun 2016
  • ||||||||||  Reolysin (pelareorep) / Oncolytics, Andrus Reo
    Enrollment change, Trial primary completion date, Combination therapy, Metastases:  Study of REOLYSIN (clinicaltrials.gov) -  Dec 5, 2015   
    P1,  N=32, Recruiting, 
    N=96 --> 0 N=20 --> 32 | Trial primary completion date: Jun 2016 --> Dec 2016
  • ||||||||||  Avastin (bevacizumab) / Roche
    New P1/2 trial, Combination therapy, Metastases:  FABLOx: Study of 5-fluorouracil (5-FU), Nab (clinicaltrials.gov) -  Dec 3, 2015   
    P1/2,  N=78, Not yet recruiting, 
  • ||||||||||  Reolysin (pelareorep) / Oncolytics, Andrus Reo
    New P1 trial, PD(L)-1 Biomarker, Metastases:  Study of Pembrolizumab With REOLYSIN (clinicaltrials.gov) -  Dec 3, 2015   
    P1,  N=9, Not yet recruiting, 
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Trial primary completion date:  Second Look Laparoscopy in Colorectal Cancer (clinicaltrials.gov) -  Nov 30, 2015   
    P2,  N=140, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Jun 2016
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  Nov 27, 2015   
    P2,  N=12, Active, not recruiting, 
    Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jul 2016
  • ||||||||||  erlotinib / Generic mfg., gemcitabine / Generic mfg.
    Enrollment closed, Trial primary completion date, Metastases:  Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Nov 24, 2015   
    P2,  N=150, Active, not recruiting, 
    Recruiting --> Suspended Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jul 2015
  • ||||||||||  leucovorin calcium / Generic mfg.
    Trial termination, Trial primary completion date:  A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) -  Nov 15, 2015   
    P2,  N=160, Terminated, 
    Active, not recruiting --> Completed Suspended --> Terminated | Trial primary completion date: Sep 2017 --> Jun 2015; Non-compliance
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion, Trial primary completion date:  RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma (clinicaltrials.gov) -  Nov 15, 2015   
    P1/2,  N=47, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Aug 2015
  • ||||||||||  Trial primary completion date:  A Phase II Study of Neoadjuvant FOLFIRINOX (clinicaltrials.gov) -  Nov 14, 2015   
    P2,  N=48, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Aug 2015 Trial primary completion date: Jul 2016 --> Dec 2016
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial primary completion date, Combination therapy, Metastases:  An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) (clinicaltrials.gov) -  Nov 10, 2015   
    P=N/A,  N=720, Active, not recruiting, 
    Active, not recruiting --> Completed | Initiation date: Apr 2008 --> Dec 2007 | Trial primary completion date: Jun 2013 --> Jun 2011 Trial primary completion date: Mar 2016 --> Oct 2016
  • ||||||||||  leucovorin calcium / Generic mfg., temozolomide / Generic mfg.
    Trial primary completion date, Combination therapy:  FOLAGLI: Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma (clinicaltrials.gov) -  Nov 9, 2015   
    P1,  N=44, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Oct 2014 --> Mar 2017
  • ||||||||||  gedatolisib (PF-05212384) / Celcuity
    Trial termination, Metastases:  A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) -  Oct 22, 2015   
    P2,  N=18, Terminated, 
    Trial primary completion date: Jun 2016 --> Oct 2016 Completed --> Terminated; B2151007 was prematurely discontinued due to Pfizer's change in prioritization for the portfolio and is not due to any safety concerns or regulatory interaction